Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions
NCT06626932 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 259
Last updated 2024-10-04
Summary
To evaluate implications of biological and procedural factors of 18-f FDG PET/CT uptake on normal organs and neoplastic lesions.
Conditions
- Oncologic Diseases
Interventions
- RADIATION
-
18 FDG (Fludeoxyglucose 18F)
18-f FDG
Sponsors & Collaborators
-
mahenoor alaa eldeen naem
lead OTHER
Eligibility
- Min Age
- 1 Year
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-31
- Primary Completion
- 2026-10-31
- Completion
- 2026-11-30
Countries
- Egypt
Study Locations
More Related Trials
-
Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer
NCT00826033 ·Status: COMPLETED
-
Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma
NCT06737835 ·Status: NOT_YET_RECRUITING
-
18F-FSPG PET/CT Imaging in Patients With Cancers
NCT03144622 ·Status: UNKNOWN
-
Usefulness of 18F-FDG PET/CT in the Initial Staging and Surveillance of Endometrial Cancer Patients
NCT05056259 ·Status: UNKNOWN
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
NCT00935090 ·Status: RECRUITING
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
NCT07110519 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
NCT02717572 ·Status: COMPLETED ·Phase: PHASE1
-
The Utility of FDG-PET for Radiation Treatment in NSCLC
NCT00385164 ·Status: UNKNOWN
-
Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT
NCT04622631 ·Status: UNKNOWN
-
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
NCT06145399 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
NCT01180751 ·Status: UNKNOWN ·Phase: PHASE3
-
Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT
NCT03519659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4
NCT04017819 ·Status: SUSPENDED ·Phase: PHASE1
-
Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients
NCT03008694 ·Status: UNKNOWN ·Phase: PHASE2
-
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
NCT02378337 ·Status: COMPLETED
-
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
NCT02323893 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer
NCT00245349 ·Status: COMPLETED
-
[18F] F-GLN by PET/CT in Breast Cancer
NCT03863457 ·Status: RECRUITING ·Phase: PHASE1
-
Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5
NCT00743353 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection
NCT02450942 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
NCT00522639 ·Status: TERMINATED ·Phase: PHASE3
-
Clinical Applications of (S)-[18F]FBFP PET/CT in Healthy Volunteers and Patients With Central Nervous System Diseases
NCT05335200 ·Status: UNKNOWN ·Phase: PHASE1
-
Molecular Pituitary Imaging Using 18F-FET PET
NCT06584123 ·Status: RECRUITING ·Phase: NA
-
Radiological Characterization of Pulmonary Involvement in Patients With Hematological Diseases
NCT06350526 ·Status: COMPLETED
-
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
NCT06557590 ·Status: RECRUITING